8-K: Celcuity Appoints Oncology Veteran Charles Romp to Board

Celcuity Inc. has expanded its Board of Directors to eight members with the appointment of Charles R. Romp, an industry veteran with over 25 years of oncology commercialization experience.

Summary

• Celcuity Inc. increased its Board of Directors from seven members to eight members.
• Charles (Chip) R. Romp was appointed as a new independent director, effective February 11, 2026, for a term extending through the 2026 Annual Meeting of Stockholders.
• Mr. Romp brings over 25 years of experience in the pharmaceutical industry, specifically in leading sales and commercial organizations within oncology.
• He is currently the Chief Executive Officer of Secura Bio and previously served as Executive Vice President, Commercial U.S., at Seagen, Inc., overseeing the commercialization of significant oncology drugs.
• Mr. Romp will receive an annual cash retainer of $50,000, payable quarterly, and an annual equity award with a fair market value of $100,000.
• Upon appointment, he was granted a pro-rated annual grant of 215 shares of restricted stock, which will vest by the earlier of the 2026 Annual Meeting or April 30, 2026.
• The appointment is expected to provide valuable commercial insight as Celcuity advances its lead therapeutic candidate, gedatolisib, towards potential approval and launch later in 2026.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive development, as the addition of a highly experienced oncology commercialization expert strengthens the company's strategic position for its lead drug candidate, gedatolisib, as it approaches market. This is a logical and beneficial step for a clinical-stage company.

Positives

• The appointment of Charles R. Romp brings over 25 years of significant oncology commercialization and sales leadership experience to the Board, enhancing strategic capabilities.
• Mr. Romp's expertise is expected to provide valuable insight as Celcuity prepares for the potential approval and launch of its lead therapeutic candidate, gedatolisib, later this year.
• The Board determined Mr. Romp qualifies as an independent director, which strengthens corporate governance and oversight.
• Gedatolisib is highlighted as having 'tremendous potential to enhance outcomes for women with breast cancer,' offering a significant opportunity for Celcuity in oncology.

Risks

• Clinical results are based on ongoing analysis of key efficacy and safety data, and interpretation of such data may change.
• There is a risk of unforeseen delays in the review of the New Drug Application (NDA) for gedatolisib by the U.S. Food and Drug Administration (FDA).
• The company's ability to obtain and maintain regulatory approvals to commercialize gedatolisib is subject to risks.
• All forward-looking statements are subject to other risks detailed in the Annual Report on Form 10-K for the year ended December 31, 2024, and subsequent filings with the Securities and Exchange Commission.

Future Outlook

The company anticipates advancing its lead therapeutic candidate, gedatolisib, towards potential FDA approval under the Real-Time Oncology Review program and commercial launch later in 2026. Ongoing Phase 3 clinical trials (VIKTORIA-1 and VIKTORIA-2) for HR+/HER2advanced breast cancer and a Phase 1/2 trial (CELC-G-201) for metastatic castration-resistant prostate cancer are progressing.

Management Comments

• "Chip brings a wealth of oncology-related commercial expertise to our Board. Chips deep experience commercializing significant oncology drugs will provide valuable insight to Celcuity as we advance our programs and prepare for the potential approval and launch of gedatolisib later this year." Brian Sullivan, Chief Executive Officer and co-founder of Celcuity.
• "Gedatolisib has tremendous potential to enhance outcomes for women with breast cancer, which gives Celcuity a very significant opportunity to build an important franchise in oncology. I am very excited to join the Board at this important moment in Celcuitys history and work with Brian and the Board to share my experience commercializing a number of pathbreaking oncology therapeutics." Charles R. Romp.

Industry Context

StockSavvy.ai notes that the appointment of a director with extensive commercial oncology experience, particularly from companies like Seagen and Genentech, is a strategic move for a clinical-stage biotechnology company like Celcuity. As Celcuity's lead candidate, gedatolisib, progresses through late-stage clinical trials and approaches potential regulatory approval, bringing in expertise in commercialization and market access is crucial for a successful product launch in the highly competitive oncology market. This aligns with a broader industry trend where companies nearing commercialization bolster their leadership with individuals who have a proven track record in bringing therapies to market.

Comparison to Industry Standards

• The appointment of a director with over two decades of specialized oncology commercialization experience, such as Mr. Romp from Seagen (known for ADCETRIS, PADCEV, TUKYSA, TIVDAK) and Genentech (AVASTIN, RITUXAN, XOLAIR), is consistent with best practices for clinical-stage biotech companies nearing commercialization.
• Comparable companies like Mirati Therapeutics, prior to its acquisition by Bristol Myers Squibb, similarly brought in seasoned commercial leaders as their oncology assets (e.g., KRAZATI) approached market.
• The compensation package, including a mix of cash and equity, is standard for independent directors in the biotechnology sector, aiming to align director interests with shareholder value.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential positive impact due to strengthened commercial expertise on the Board, which could improve the likelihood of successful gedatolisib commercialization and future revenue generation.
• Employees: Potential positive impact through enhanced strategic direction and clearer path to market for key products, potentially leading to company growth and stability.
• Customers (future): Improved strategic planning for market entry of gedatolisib could lead to more effective product availability and patient access.

Next Steps

• Advancement of gedatolisib programs through ongoing clinical trials.
• Preparation for potential FDA approval and commercial launch of gedatolisib later in 2026.
• Continuation of Phase 3 VIKTORIA-2 clinical trial enrollment for HR+/HER2advanced breast cancer.
• Continuation of Phase 1/2 CELC-G-201 clinical trial for metastatic castration-resistant prostate cancer.
• The 2026 Annual Meeting of Stockholders, at which Mr. Romp's term will conclude unless re-elected.

Key Dates

Recommendation

The appointment of a highly experienced director like Charles Romp is a positive strategic move for Celcuity, particularly as it nears potential commercialization of gedatolisib. This strengthens the company's capabilities for market entry and execution. However, as a clinical-stage company, significant risks remain tied to clinical trial outcomes, regulatory approvals, and the competitive landscape. While the appointment is a good signal for future commercial efforts, it does not fundamentally alter the immediate risk profile or provide new financial performance data. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive strategic enhancement while awaiting further clinical and regulatory milestones.

Keywords

Celcuity, CELC, Board of Directors, Charles Romp, Chip Romp, Director Appointment, Oncology, Biotechnology, Pharmaceutical Industry, Commercialization, Gedatolisib, SEC Filing, 8-K, Corporate Governance, Clinical Stage